Lantheus Holdings Inc. — LNTH-2501 (Gallium-68 edotreotide) · Neuroendocrine tumors (NETs) in adult and pediatri.
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (1/9/26) through T+5. Run-up high $109.01 on 6/25/26, low $64.25 on 1/23/26 (T-120 to T-1). FDA decision 6/26/26. Historical price action, not a forecast.
Key facts
FDA decision date2026-06-26
OutcomeCRL
Drug / candidateLNTH-2501 (Gallium-68 edotreotide)